2022 Revenues ($USD) : $19,263,000,000.00
2022 R&D spend : $3,295,000,000.00
2022 Number of Employees : 3,900
Fiscal Year End : 12/31/22
Leader : CEO Stéphane Bancel

Moderna is a relatively new player in the pharmaceutical industry, but it has quickly established itself with its mRNA technology platform. As of late May 2023, however, its shares had fallen more than 22% YTD to $139. Part of the reason is that its business continues to be highly reliant on its primary commercialized product, the Spikevax COVID-19 vaccine. The product has been highly successful, with $17.7 billion in sales as of the end of 2022, but demand is tapering. Moderna has projected that the vaccine will generate $21 billion in annual sales as of March 2023. The company, however, is also actively involved in developing a range of next-ge COVID-19 vaccines, as well as several other mRNA-based products for cancer, autoimmune and infectious diseases. The company currently has more than 40 product candidates under development. In the fiscal year ended December 31, 2022, Moderna had an annual revenue of $19.3 billion with an annual R&D spend of $3.3 billion. —BB